News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Antonio Calles: Choose your path after MARIPOSA and COCOON trial presentations at ELCC25
Antonio Calles/X
Mar 28, 2025, 15:18

Antonio Calles: Choose your path after MARIPOSA and COCOON trial presentations at ELCC25

Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared a post on X:

“So this is the situation in Paris tonight after high OS MARIPOSA trial and low toxicity within COCOON trial presentations.

Choose your path.”

More posts featuring Antonio Calles.

Antonio Calles cancer COCOON ELCC25 MARIPOSA OncoDaily Oncology
Special Coverage
Blog Posts
Aug 18, 2025, 20:57
Niranjala Siriwardena: Why I’m Fighting for Australia’s First Workplace Cancer Survivorship Policy
Voices
Aug 18, 2025, 20:47
Wafaa M Rashed: Final Words to the Tenth Cohort of the Policy Advocacy in Genetics and Genomics Course
Blog Posts
Aug 18, 2025, 20:36
Gashaw Arega: The Beginning of Childhood Cancer Care in Ethiopia
Opinion
Aug 18, 2025, 20:22
Soumen Das: From LMIC to LRS - Rethinking Global Health
Health Policy
Aug 18, 2025, 20:12
Niranjala Siriwardena: Building Australia’s First Workplace Cancer Survivorship Policy
Voices
Aug 18, 2025, 20:02
Confronting Stigma at the Crossroads of Hepatitis and Cancer - European Cancer Organisation
Positive
Aug 18, 2025, 19:53
Erin and Chloe Raise £800 for Lung Cancer Research - Oncogene Cancer Research
Blog Posts
Aug 18, 2025, 19:28
Liz O’Riordan: Everything You Need to Know about Breast Cancer Recurrence
Blog Posts
Aug 18, 2025, 19:17
Matteo Bauckneht: Pitfalls in PSMA-Based RLT - A Case-Based Review at EANM25
Insight
Aug 18, 2025, 18:55
NCODA Brings the BREAKWATER Trial into Practice
Blog Posts
Aug 18, 2025, 18:20
Amol Akhade: Key Late-Breaking and Practice-Changing Trials to Watch at WCLC 2025
Insight
Aug 18, 2025, 18:09
Hung Trinh Highlights Pasritamig, a First-in-Class T-Cell Engager for Prostate Cancer